Mitochondrial failure emerges as the common thread in diabetic nerve damage

A new review links energy failure in mitochondria to oxidative stress, inflammation and axon destruction, pointing to potential treatments beyond blood-sugar control.

A new review in the Journal of Translational Medicine argues that diabetic neuropathy is driven by far more than persistently high blood sugar. The paper, led by Xiaotong Wu and Shihong Chen of the Second Qilu Hospital of Shandong University, says damaged mitochondria sit at the centre of the disease, linking metabolic stress, inflammation and the gradual breakdown of nerves. Published on 17 October 2026, the review frames mitochondrial failure as the common thread running through the condition’s many forms, from painful sensory neuropathy to silent loss of feeling in the feet. The same theme appears in broader reviews of the field, which also point to oxidative stress, inflammatory signalling and impaired mitochondrial biology as key drivers of nerve damage.

The authors argue that diabetic neuropathy cannot be explained by glucose alone. Peripheral nerves have exceptionally high energy demands, particularly along the longest axons that reach the feet, and depend on mitochondria to produce adenosine triphosphate, the molecule that powers cellular activity. When those organelles fail, Schwann cells, sensory neurons and autonomic nerves are among the first to suffer. That helps explain why symptoms often begin distally, with numbness, burning pain or loss of sensation in the toes and feet before spreading more widely.

At the biochemical level, the review describes a chain reaction set off by hyperglycaemia, lipid overload and microvascular injury. These stresses disrupt the electron transport chain, the system inside mitochondria that helps generate energy. As that process becomes less efficient, reactive oxygen species rise, damaging mitochondrial DNA, membrane lipids and other cellular structures. Calcium balance also breaks down. Excess calcium enters the mitochondria, and prolonged stress can trigger a catastrophic opening of the mitochondrial permeability transition pore, collapsing the energy gradient the cell depends on. A separate review in Antioxidants likewise links diabetic neuropathy to mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress and chronic inflammation.

The paper also stresses that mitochondria are not static power units. They must be constantly divided, fused, transported and recycled to remain healthy. In diabetes, that balance appears to tip towards fragmentation. The molecular machinery that moves mitochondria down long nerve fibres also becomes less effective, depriving distant axon terminals of energy. Quality-control systems such as mitophagy, which clears away damaged mitochondria through the PINK1-Parkin pathway, are impaired as well. A scoping review published in the International Journal of Molecular Sciences, which mapped 853 studies from January 2010 through August 2026, reached a similar conclusion and said mitochondrial quality-control defects remain one of the most important gaps in the field.

One of the most important points in the review is the link between mitochondrial failure and SARM1, a protein that can drive axon destruction. When mitochondrial dysfunction lowers levels of NAD+, a crucial metabolic cofactor, SARM1 is activated and consumes what remains, pushing the axon into a self-destruct sequence. The authors also describe how damaged mitochondria can ignite inflammation by releasing signals that activate the NLRP3 inflammasome and by leaking mitochondrial DNA into the cytoplasm, where it can trigger the cGAS-STING pathway. In their telling, energy failure and neuroinflammation are not separate processes but parts of the same cascade.

The review argues that these mechanisms help explain why diabetic neuropathy takes different clinical forms yet still shares a common biological core. In painful diabetic peripheral neuropathy, mitochondrial stress in sensory neurons and nearby glial cells appears to amplify pain. In less symptomatic disease, the same bioenergetic collapse can quietly destroy distal nerve fibres, leaving feet numb and vulnerable to ulcers. The authors also point to corneal small-fibre neuropathy, cardiovascular autonomic neuropathy and even central nervous system injury in diabetes as conditions that show overlapping mitochondrial signatures. Other recent work, including a review on diabetes and mitochondrial transplantation, suggests that restoring mitochondrial function may eventually become a therapeutic strategy rather than simply a mechanistic explanation.

That possibility remains far from proven in patients. The review says exercise and diet can support mitochondrial biogenesis, while experimental treatments are being developed to target SARM1, calcium overload, mitophagy defects and mitochondrial oxidative stress. Among the candidates discussed are mitochondria-directed antioxidants such as MitoQ and MitoTEMPO, which are designed to accumulate inside the organelle more effectively than conventional antioxidants. The authors also note interest in natural compounds and traditional Chinese medicine, but stress that these approaches still need rigorous testing. What is missing, they say, are high-quality human trials that measure nerve structure and function directly and validate whether the treatment is reaching its mitochondrial target.

For clinicians and researchers, the broader message is that diabetic neuropathy may need to be treated as a disease of failing cellular energy systems, not just high glucose or pain. The review’s authors say future studies should be guided by biomarkers, patient stratification and nerve-specific outcome measures rather than by symptoms alone. As diabetes rates continue to rise and no disease-modifying treatment has been approved for diabetic neuropathy, the paper presents mitochondria as a promising but still unproven therapeutic frontier.